Please assess the completion status of the following clinical trial:

Trial Title: PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults, males and females, ages 18 to 45 yrs, with BMI 19 to 30 kg/m2~* Women of childbearing potential must have negative pregnancy test and agree to use an acceptable method of highly effective contraceptive~* Men must either have a vasectomy or agree to use highly effective contraception~Exclusion Criteria:~* Prior or current clinically significant medical illness or disorder~* Has celiac disease or type 1 diabetes or related autoantibodies~* Has active acute or chronic/latent infection, or history of recent serious infection~* Recent acute illness or recent major illness, hospitalization or surgery~* Recent history of alcohol or drug abuse~* Received an experimental antibody or biologic therapy in last 6 months~* Received live, inactivated or subunit virus vaccine or a bacterial vaccine within last 4 weeks~* Intolerance or hypersensitivity to vaccines or vaccine components or has a drug or food allergy or allergic disease requiring medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1, Low Dose, Placebo (Type: PLACEBO_COMPARATOR): Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
- Cohort 1, Low Dose, PRV-101 (Type: EXPERIMENTAL): Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
- Cohort 2, High Dose, Placebo (Type: PLACEBO_COMPARATOR): High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
- Cohort 2, High Dose, PRV-101 (Type: EXPERIMENTAL): High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).